In conclusion, this study provides a comprehensive investigation into the potential of Cdk5 inhibitors, particularly BLINK11, in addressing both peripheral and cognitive complications associated with T2D induced by an HFD. The gene discussed is CDK5; the disease is type 2 diabetes mellitus.